Overview


  • Pfizer Inc.
  • Merck & Co, Inc.
  • Lupin
  • Janssen Biotech Inc.
  • Hoffmann-La Roche Ltd.
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Pacira Pharmaceuticals Inc.
  • Celgene Corporation and Bausch & Lomb Incorporated
  • among others
??
Tier 1 players- established companies in the market with a major market share
??
Tier 2 players
??
Emerging players which are growing rapidly
??
New Entrants
FutureWise Key Takeaways
??
Growth prospects
??
SWOT analysis
??
Key trends
??
Key data points affecting market growth
??
To provide an exhaustive analysis on injectable nanomedicines by drug type, by application and region
??
To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
??
To evaluate and forecast micro-markets and overall market
??
To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
??
To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
??
Profiling of companies to evaluate their market shares, strategies, financials and core competencies

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Injectable Nanomedicines Market Variables, Trends
    • Scope
        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances
  • 5.   Global Injectable Nanomedicines Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Injectable Nanomedicines Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Injectable Nanomedicines Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Injectable Nanomedicines Market, By Drug Type Historical Analysis and Forecast 2020-2027 (USD Million)
    •     1. Liposomes

          2. Micelles

          3. Nanocrystals

          4. Polymeric Nanoparticles

          5. Metallic Nanoparticles

          6. Mesoporous Silica Nanoparticles

          7. Others

  • 8.  Global Injectable Nanomedicines Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)
    • 1. Cancers

                 2. Central Nervous System Diseases

                 3. Cardiovascular diseases

                 4. Infection Control

                 5. Inflammatory Diseases

  • 9.  Global Injectable Nanomedicines Market, By End-User Historical Analysis and Forecast 2020-2027 (USD Million)
    • 1. Hospitals
                 2. Ambulatory Surgical Centers
                 3. Clinics
                 4. Specialized Drugs R&D Institutes

                 5. Managed Care Organizations

  • 10.  North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    •   1. Introduction

                 2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

                           2.1. U.S.A

                           2.2. Canada

                           2.3. Mexico

                 3. Market Size (USD Million) Forecast for North America 2020-2027

  • 11.  Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    •       1. Introduction

                 2. Regional Market Trends

                 3. Historical Market Size (USD Million) Analysis By Country, 2015-2019

                           3.1. Brazil

                           3.2. Venezuela

                           3.3. Argentina

                           3.4. Rest of Latin America

                 4. Market Size (USD Million) Forecast for Latin America 2020-2027 

  • 12.  Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    • 1. Introduction

                 2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

                           2.1. Germany

                           2.2. U.K

                           2.3. France

                           2.4. Italy

                           2.5. Spain

                           2.6. Russia

                           2.7. Poland

                           2.8. Switzerland

                           2.9. Rest of Western Europe

                 3. Market Size (USD Million) Forecast for Europe 2020-2027

  • 13.   Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    •   1. Introduction

                 2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

                           2.1. Japan

                           2.2. China

                           2.3. Singapore

                           2.4. India

                           2.5. Australia and New Zealand

                           2.6. ASEAN

                           2.7. South Korea

                           2.8. Taiwan

                           2.9. Rest of Asia Pacific

                 3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027

       

  • 14.  Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    •   1. Introduction

                 2. Historical Market Size (USD Million) Analysis By Country, 2015-2019

                           2.1. Saudi Arabia

                           2.2. UAE

                           2.3. South Africa

                           2.4. Egypt

                 3. Market Size (USD Million) Forecast for MEA 2020-2027

  • 15.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
    •  1. Pfizer Inc.

                           1.1. Company Overview

                           1.2. Product Portfolio

                           1.3. SWOT Analysis

                           1.4. Financial Overview

                           1.5. Strategic Overview

                 2. Merck & Co, Inc.

                           2.1. Company Overview

                           2.2. Product Portfolio

                           2.3. SWOT Analysis

                           2.4. Financial Overview

                           2.5. Strategic Overview

                 3. Lupin, Janssen Biotech Inc.

                           3.1. Company Overview

                           3.2. Product Portfolio

                           3.3. SWOT Analysis

                           3.4. Financial Overview

                           3.5. Strategic Overview

                 4. Hoffmann-La Roche Ltd.

                           4.1. Company Overview

                           4.2. Product Portfolio

                           4.3. SWOT Analysis

                           4.4. Financial Overview

                           4.5. Strategic Overview

                 5. Amgen Inc.

                           5.1. Company Overview

                           5.2. Product Portfolio

                           5.3. SWOT Analysis

                           5.4. Financial Overview

                           5.5. Strategic Overview

                 6. Teva Pharmaceutical Industries Ltd.

                           6.1. Company Overview

                           6.2. Product Portfolio

                           6.3. SWOT Analysis

                           6.4. Financial Overview

                           6.5. Strategic Overview

                 7. Pacira Pharmaceuticals Inc.

                           7.1. Company Overview

                           7.2. Product Portfolio

                           7.3. SWOT Analysis

                           7.4. Financial Overview

                           7.5. Strategic Overview

                 8. Celgene Corporation

                           8.1. Company Overview

                           8.2. Product Portfolio

                           8.3. SWOT Analysis

                           8.4. Financial Overview

                           8.5. Strategic Overview

                 9. Bausch & Lomb Incorporated

                           9.1. Company Overview

                           9.2. Product Portfolio

                           9.3. SWOT Analysis

                           9.4. Financial Overview

                           9.5. Strategic Overview

       

  • 16.  Impact of COVID-19
    •   1. Positive influence on the healthcare industry

            2. The financial disruption of the manufacturing sector

            3. Impact of COVID-19 on emerging companies

            4. Significant mandates in the healthcare regulations initiated by administrations

            5. The overall economic slowdown of the developing and developed nations

       

  • 17.  Competitive Intelligence and Competitive Matrix
    •   17.1 Competitive Intelligence

            17.2 Competitive Matrix

       

  • 18.  Major Deals and Strategic Alliances Analysis
    •   18.1 Joint ventures

            18.2 Mergers and acquisitions

            18.3 Licensing and partnerships

            18.4 Technology Collaborations

            18.5 Strategic Divestments

            18.6 Market Entry Strategies                 

       

  • 19.   Relevant Case Studies and Latest News Updates
  • 20.   Key Market Takeaway Points from the Market Analysts at Future Market Analytics
Partner

Our Clients